Royal Brompton & Harefield Hospitals NHS Trust

=LEFT(J113,6)

Quality of secondary prevention following percutaneous coronary interventions in North West London

Objective: To evaluate achievement of guideline directed targets for cholesterol levels in patients with a history of stable coronary artery disease or acute coronary syndromes Primary endpoints: Percentage of patients within target cholesterol levels Secondary endpoints: Recurrent events including death, MI, stroke and unplanned revascularization. Percentage of patients taking high intensity statin therapy (Rosuvastatin 20mg/40mg or Atorvastatin 80mg or Simvastatin 80mg). Percentage of patients taking statin + ezetimibe reaching target cholesterol levels. Principle research question: Quality of secondary prevention of patients with acute coronary syndromes undergoing PCI. Scientific justification: Firstly, non-HDL cholesterol has been shown to be an important cause and predictor of clinical outcomes in patients with coronary artery disease. Secondly, Mendelian randomization studies have shown that lifelong sustained reductions in LDL cholesterol are associated with a lower risk of atherosclerotic disease. Thirdly, randomized controlled trials have demonstrated a reduction in cardiovascular events in patients who had acute coronary syndromes and were treated with statins and/or ezetimibe. Therefore, it is an important public health issue to address the adherence to target cholesterol levels from the European Society of Cardiology Guidelines on Cardiovascular Disease Prevention in Clinical Practice (2016) and the Guidelines for the management of dyslipidemias (2019). Target publication: European Society of Cardiology Congress as a “Registry Hotline” submission.

16/06/2022

TRE